Cargando…
Use of SGLT2 Inhibitors Reduces Heart Failure and Hospitalization: A Multicenter, Real-World Evidence Study
BACKGROUND: New research has produced evidence to support the use of diabetic drugs to prevent heart failure (HF). However, evidence of their effect in real-world clinical practice is limited. OBJECTIVE: The objective of this study is to establish whether real-world evidence supports clinical trial...
Autores principales: | Blanco, Christopher Antonio, Garcia, Kara, Singson, Adrian, Smith, William R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Permanente Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013722/ https://www.ncbi.nlm.nih.gov/pubmed/36913542 http://dx.doi.org/10.7812/TPP/22.137 |
Ejemplares similares
-
SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021) -
Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure
por: Nakagaito, Masaki, et al.
Publicado: (2023) -
SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023) -
SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world
por: Marx, Nikolaus, et al.
Publicado: (2023) -
Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)